Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.57 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.57 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4217230 | 0.80 | PIM1 (0.64) | PIM1PIM2PIM3MAPTLMNA | |
| SCHEMBL4212674 | 0.76 | PIM1 (0.79) | PIM1PIM2PIM3 | |
| SCHEMBL16619153 | 0.74 | ALDH1A1 (0.57) | PIM1PIM2ALDH1A1MAPTLMNA | |
| SCHEMBL960306 | 0.73 | MAPT (0.62) | MAPTSMN1; SMN2RXFP1GAA | |
| SCHEMBL4212895 | 0.73 | PIM1 (0.79) | PIM1PIM2PIM3 | |
| SCHEMBL2064236 | 0.73 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL4206198 | 0.73 | PIM1 (1.00) | PIM1PIM2PIM3 | |
| SCHEMBL4212666 | 0.73 | PIM1 (0.68) | PIM1PIM2PIM3 | |
| SCHEMBL4209814 | 0.71 | PIM1 (0.68) | PIM1PIM2PIM3 | |
| SCHEMBL4210288 | 0.71 | PIM1 (1.00) | PIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885PIM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.